Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Haleon Plc (HLN) covers the month of February 2025, with the report dated February 3, 2025. Haleon is a global leader in consumer health, operating across five categories: Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals, and Supplements (VMS). The company markets well-known brands including Advil, Sensodyne, Panadol, and Centrum.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and capital structure updates rather than financial performance.
Material Changes and Capital Structure
The primary disclosure concerns the company's share capital as of January 31, 2025:
- Total Issued Shares: 9,083,725,919 ordinary shares of £0.01 each.
- Treasury Shares: 29,580,205 shares held in treasury.
- Voting Rights: 9,054,145,714 ordinary shares carry voting rights.
This voting share count serves as the denominator for shareholders to calculate notifiable interests under the FCA's Disclosure Guidance and Transparency Rules.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on performance, specific risks, contingencies, or unusual items. The document is a routine notification of voting rights.
Key Facts for Investor Verification
- Verify the denominator for notifiable interest calculations is 9,054,145,714 shares.
- Confirm the treasury share count of 29,580,205 as of January 31, 2025.
- Note that this filing contains no financial results; investors should refer to the most recent Form 20-F or quarterly earnings release for performance data.